



ICH
harmonisation for better health

ICH Q3C(R8) – Residual Solvent

Step 2 document – to be released for comments

March 26, 2020

International Council for Harmonisation of Technical Requirements
for Pharmaceuticals for Human Use



ICH Q3C(R8) – Residual Solvents (Step 2)

Legal Notice

- This presentation is protected by copyright and may, with the exception of the ICH logo, be used, reproduced, incorporated into other works, adapted, modified, translated or distributed under a public license provided that ICH's copyright in the presentation is acknowledged at all times. In case of any adaption, modification or translation of the presentation, reasonable steps must be taken to clearly label, demarcate or otherwise identify that changes were made to or based on the original presentation. Any impression that the adaption, modification or translation of the original presentation is endorsed or sponsored by the ICH must be avoided.
- The presentation is provided "as is" without warranty of any kind. In no event shall the ICH or the authors of the original presentation be liable for any claim, damages or other liability arising from the use of the presentation.
- The above-mentioned permissions do not apply to content supplied by third parties. Therefore, for documents where the copyright vests in a third party, permission for reproduction must be obtained from this copyright holder.

Background – Q3C Maintenance

- The ICH Q3C core guideline reached *Step 4* in 1997.
- In 1999 a maintenance agreement was instituted and a Maintenance Expert Working Group (EWG) was formed.
- The agreement provided for the re-visitation of solvent Permitted Daily Exposure (PDE) and allowed for minor changes to the guideline that included the existing PDEs.
- It was also agreed that new solvents and PDEs could be added based upon adequate toxicity data.

Background

- This 8th revision (R8) of the document has been signed off as a *Step 2* document (25 March 2020) to be issued by the ICH Regulatory Members for public consultation
- The document was originally developed based on a Concept Paper (10 March 1994)
- Anticipating finalization as a *Step 4* document to be implemented in the local regional regulatory system: July 2020

Guideline Objectives

- **The objectives of the current Maintenance procedure are to add three new solvents to the guideline:**
 - 2-Methyltetrahydrofuran
 - Cyclopentyl Methyl Ether
 - Tertiary Butyl Alcohol

Table of Contents

- **2-Methyltetrahydrofuran**
 - Toxicological data
 - Proposed PDE
- **Cyclopentyl Methyl Ether**
 - Toxicological data
 - Proposed PDE
- **Tertiary Butyl Alcohol**
 - Toxicological data
 - Proposed PDE

2-Methyltetrahydrofuran (2-MTHF)

- EWG's review of available toxicity data with 2-MTHF
 - Genotoxicity: no evidence for genotoxicity
 - Carcinogenicity: no data available
 - Reproductive toxicity: no reliable studies for PDE calculation
 - Repeat dose toxicity: two rat sub-chronic oral studies; No-observed-effect-level (NOEL) considered appropriate for PDE calculation

2-MTHF: PDE calculation*

*see Q3C guideline for details of PDE calculation

- Rat sub-chronic (3-month) oral studies
 - Effects at 500 mg/kg/day or greater included changes in kidney weight, cholesterol, prothrombin time, and hepatocellular hypertrophy
 - NOEL of 250 mg/kg/day used for PDE
 - **PDE = 50 mg/day**
- Since the PDE is greater than or equal to 50 mg/day, 2-MTHF is placed into Class 3 (“solvents with low toxic potential”)

Cyclopentyl methyl ether (CPME)

- EWG's review of available toxicity data with CPME
 - Genotoxicity: no evidence for genotoxicity
 - Carcinogenicity: no data available
 - Reproductive toxicity: a 2-generation study in rats demonstrated decreased body weights of pups; however, detailed information from study is not available.
 - Repeat dose toxicity: two rat sub-chronic oral studies and one rat sub-chronic inhalation study; No-observed-effect-level (NOEL) from rat 28-day oral study considered most appropriate for PDE calculation.

CPME: PDE calculation*

*see Q3C guideline for details of PDE calculation

- Rat sub-chronic (28-day) oral study
 - Effects at 700 mg/kg/day (high dose) included lethality, salivation, increased respiration, and CNS effects.
 - NOEL of 150 mg/kg/day (mid dose) used for PDE
 - PDE = 15 mg/day
- Since CPME is associated with significant toxicities and a PDE of 15 mg/day, CPME is placed into Class 2 (“solvents to be limited”)

Tertiary butyl alcohol (TBA) - 1

- EWG's review of available toxicity data with TBA
 - Genotoxicity: no evidence for genotoxicity
 - Reproductive toxicity: limited data available.
 - Some evidence of induced developmental delays and mortality at relatively high oral doses.
 - Additional reports of reduced mean litter size, number of live born pups and pup body weight, and increased pup mortality and number of stillborn pups.

Tertiary butyl alcohol (TBA) - 2

- EWG's review of available toxicity data with TBA
 - Repeat dose toxicity: two sub-chronic oral (drinking water) studies in rats and mice
 - In rats:
 - Lethality observed at highest dose (2824 mg/kg/day)
 - Other key findings included nephropathy and hyperplasia/inflammation of the urinary bladder.
 - Lowest-observed-effect-level (LOEL) of 176 mg/kg/day identified due to increased incidence of nephropathy.
 - In mice:
 - Lethality observed at highest dose (7143 mg/kg/day)
 - Other key findings included reduced body weight and hyperplasia/inflammation of the urinary bladder at the two highest doses
 - NOEL of 1786 mg/kg/day was identified.

Tertiary butyl alcohol (TBA) - 3

- EWG's review of available toxicity data with TBA
 - Carcinogenicity:
 - TBA was studied in 2-year rat and mouse drinking water studies
 - Primary targets of TBA toxicity and carcinogenicity were the kidney in rats, and thyroid gland and urinary bladder in mice
 - NTP's conclusion: "some evidence of carcinogenic activity" in male rats and female mice
 - The 2-year carcinogenicity studies were considered the most appropriate to support calculation of the PDE
 - Individual PDEs were calculated for each study (see following slides)

TBA: PDE calculation* - 1

*see Q3C guideline for details of PDE calculation

- Rat 2-year study:
 - Renal lesions and tumour findings in male rats are not relevant to humans
 - Increased severity in nephropathy observed in female rats at all doses used for PDE calculation (LOEL = 175 mg/kg/day)
 - PDE = 35 mg/day

TBA: PDE calculation* - 2

*see Q3C guideline for details of PDE calculation

- Mouse 2-year study:
 - Thyroid adenomas increased in high dose females
 - Increased incidence and severity of thyroid follicular hyperplasia in TBA-treated groups used for PDE calculation (LOEL = 510 mg/kg/day)
 - Increased incidence of urinary bladder inflammation and hyperplasia of transitional epithelium at high dose
 - PDE = 42.5 mg/day

TBA: PDE calculation* - 3

*see Q3C guideline for details of PDE calculation

- The overall PDE was identified as 35 mg/day
- Since TBA is associated with significant toxicities and a PDE of 35 mg/day, TBA is placed into Class 2 (“solvents to be limited”)

Conclusions

- **A Q3C Maintenance procedure has been initiated to add 3 new solvents: 2-MTHF, CPME, and TBA**
- **The proposed PDEs are as follows:**
 - 2-MTHF: 50 mg/day (Class 3)
 - CPME: 15 mg/day (Class 2)
 - TBA: 35 mg/day (Class 2)

Contact

- **For any questions please contact the ICH Secretariat:**

admin@ich.org